Scientists have developed compounds that selectively block a crucial interaction between RAS and the enzyme PI3K, a driver of tumor growth. Scientists from the Francis Crick Institute and Vividion The ...

Clinical benefit of the gedatolisib regimens was consistent across patient subgroups Hyperglycemia was reported in only 9.2% of patients treated with gedatolisib + palbociclib + fulvestrant ...

Endocrine therapy typically slows cell cycle progression by reducing cyclin D1, which partners with CDK4/6 to promote cell ...

Glioblastoma (GBM), a malignant tumor originating from glial, is the most common primary tumor of the central nervous system and the most aggressive form of glioma. Despite surgery, radiation, and ...

When cancer progresses on endocrine therapy, the next step is likely either a biopsy to gather tissue for testing or a liquid ...

A comprehensive, multi-phase investigation published in Advanced Science suggests that the amino acid tryptophan (Trp) may be a key determinant of therapeutic response to conventional synthetic ...

Celcuity Inc. surges to a $2B valuation on strong phase 3 data for gedatolisib in hormone-positive breast cancer. Read why ...

Researchers found that 160 milligrams of daily aspirin significantly lowered cancer recurrence risk for colorectal patients ...

This review systematically examines the potential of spices and culinary herbs (e.g., turmeric, garlic, ginger) for breast cancer (BC) prevention and treatment, elucidating their underlying mechanisms ...

FMC-242 is a potentially best-in-class covalent allosteric inhibitor that breaks the interaction between PI3Kα and RAS, ...

Researchers at the Francis Crick Institute and Vividion Therapeutics have identified chemical compounds that can precisely ...